149 related articles for article (PubMed ID: 37081619)
1. Predictive Values of Blood Type I and Type II Interferon Production for Disease Activity and Clinical Response to TNF-α Blocking Therapy in Patients with Ankylosing Spondylitis.
Hu Y; Lou B; Jiang Z; Yu C
Tohoku J Exp Med; 2023 Jul; 260(3):263-271. PubMed ID: 37081619
[TBL] [Abstract][Full Text] [Related]
2. Predictive values of circulating miR-146a and miR-155 for disease activity and clinical response to TNF-α blocking therapy in patients with ankylosing spondylitis.
Liu L; Hu X
Int J Rheum Dis; 2024 Jan; 27(1):e15004. PubMed ID: 38152051
[TBL] [Abstract][Full Text] [Related]
3. Interferon-alpha 1 expression indicates the disease activity and response of patients with ankylosing spondylitis to anti-TNF-α treatment.
Li H; Liu J; Ji X
Mod Rheumatol; 2024 Mar; 34(3):592-598. PubMed ID: 37022149
[TBL] [Abstract][Full Text] [Related]
4. Non-steroidal anti-inflammatory drugs in patients with stable ankylosing spondylitis receiving tumor necrosis factor inhibitor: continued vs withdrawn.
Park JH; Kwon OC; Park MC
Clin Rheumatol; 2020 Dec; 39(12):3669-3675. PubMed ID: 32447601
[TBL] [Abstract][Full Text] [Related]
5. Baseline predictors of response and discontinuation of tumor necrosis factor-alpha blocking therapy in ankylosing spondylitis: a prospective longitudinal observational cohort study.
Arends S; Brouwer E; van der Veer E; Groen H; Leijsma MK; Houtman PM; Th A Jansen TL; Kallenberg CG; Spoorenberg A
Arthritis Res Ther; 2011 Jun; 13(3):R94. PubMed ID: 21689401
[TBL] [Abstract][Full Text] [Related]
6. PBMC CDC42 reveals the disease activity and treatment efficacy of TNF inhibitor in patients with ankylosing spondylitis.
Zhang Q; Jin D; Mou X; Ye H
J Clin Lab Anal; 2022 Mar; 36(3):e24267. PubMed ID: 35104386
[TBL] [Abstract][Full Text] [Related]
7. Tumor necrosis factor-α promoter -308/238 polymorphism association with less severe disease in ankylosing spondylitis is unrelated to serum TNF-α and does not predict TNF inhibitor response.
Nossent JC; Sagen-Johnsen S; Bakland G
J Rheumatol; 2014 Aug; 41(8):1675-82. PubMed ID: 25028373
[TBL] [Abstract][Full Text] [Related]
8. [Relapse of ankylosing spondylitis and its predictors after withdrawal of tumor necrosis factor-α inhibitors: a 52-week follow-up study].
Tang C; Chen F; Zheng S; Wu L; Chen S; Zhu J; Li J
Nan Fang Yi Ke Da Xue Xue Bao; 2021 May; 41(5):633-639. PubMed ID: 34134948
[TBL] [Abstract][Full Text] [Related]
9. Interferon-related gene expression in response to TNF inhibitor treatment in ankylosing spondylitis patients: a pilot study.
Harrison SR; Burska AN; Emery P; Marzo-Ortega H; Ponchel F
Rheumatology (Oxford); 2021 Aug; 60(8):3607-3616. PubMed ID: 33393636
[TBL] [Abstract][Full Text] [Related]
10. Clinical efficacy of alternative TNF inhibitor and secukinumab between primary non-responder and secondary non-responder of prior TNF inhibitor in ankylosing spondylitis.
Min HK; Kim HR; Lee SH; Hong YS; Kim MY; Park SH; Kang KY
Mod Rheumatol; 2023 Jan; 33(1):194-201. PubMed ID: 35107167
[TBL] [Abstract][Full Text] [Related]
11. Long noncoding RNA intersectin 1-2 gradually declines during adalimumab treatment, and its reduction correlates with treatment efficacy in patients with ankylosing spondylitis.
Li M; Zhou X
Inflammopharmacology; 2021 Oct; 29(5):1371-1378. PubMed ID: 34406596
[TBL] [Abstract][Full Text] [Related]
12. An international study on starting tumour necrosis factor-blocking agents in ankylosing spondylitis.
Pham T; Landewé R; van der Linden S; Dougados M; Sieper J; Braun J; Davis J; Rudwaleit M; Collantes E; Burgos-Vargas R; Edmonds J; Olivieri I; van der Horst-Bruinsma I; Mielants H; Stone M; Emery P; van der Heijde D
Ann Rheum Dis; 2006 Dec; 65(12):1620-5. PubMed ID: 16464984
[TBL] [Abstract][Full Text] [Related]
13. Treatment of ankylosing spondylitis with TNF inhibitors does not have adverse effect on results of liver function tests: a longitudinal study.
Capkin E; Karkucak M; Cosar AM; Ak E; Karaca A; Gokmen F; Budak BS; Tosun M
Int J Rheum Dis; 2015 Jun; 18(5):548-52. PubMed ID: 24612551
[TBL] [Abstract][Full Text] [Related]
14. Down-regulation of the nonspecific and antigen-specific T cell cytokine response in ankylosing spondylitis during treatment with infliximab.
Zou J; Rudwaleit M; Brandt J; Thiel A; Braun J; Sieper J
Arthritis Rheum; 2003 Mar; 48(3):780-90. PubMed ID: 12632433
[TBL] [Abstract][Full Text] [Related]
15. Predicting Probability of Response to Tumor Necrosis Factor Inhibitors for Individual Patients With Ankylosing Spondylitis.
Wang R; Dasgupta A; Ward MM
JAMA Netw Open; 2022 Mar; 5(3):e222312. PubMed ID: 35289857
[TBL] [Abstract][Full Text] [Related]
16. Response to Tumor Necrosis Factor Inhibition in Male and Female Patients with Ankylosing Spondylitis: Data from a Swiss Cohort.
Hebeisen M; Neuenschwander R; Scherer A; Exer P; Weber U; Tamborrini G; Micheroli R; Wildi LM; Zufferey P; Nissen MJ; Villiger PM; Bernhard J; Finckh A; van der Horst-Bruinsma IE; Sieper J; Landewé R; van der Heijde D; Ciurea A;
J Rheumatol; 2018 Apr; 45(4):506-512. PubMed ID: 29449504
[TBL] [Abstract][Full Text] [Related]
17. Disease Activity Cutoff Values in Initiating Tumor Necrosis Factor Inhibitor Therapy in Ankylosing Spondylitis: A German GO-NICE Study Subanalysis.
Braun J; Baraliakos X; Kiltz U; Krüger K; Burmester GR; Wassenberg S; Thomas MH
J Rheumatol; 2020 Jan; 47(1):35-41. PubMed ID: 30877206
[TBL] [Abstract][Full Text] [Related]
18. Low sclerostin levels: a predictive marker of persistent inflammation in ankylosing spondylitis during anti-tumor necrosis factor therapy?
Saad CG; Ribeiro AC; Moraes JC; Takayama L; Goncalves CR; Rodrigues MB; de Oliveira RM; Silva CA; Bonfa E; Pereira RM
Arthritis Res Ther; 2012 Oct; 14(5):R216. PubMed ID: 23062122
[TBL] [Abstract][Full Text] [Related]
19. Levels of circulating Th17 cells and regulatory T cells in ankylosing spondylitis patients with an inadequate response to anti-TNF-α therapy.
Xueyi L; Lina C; Zhenbiao W; Qing H; Qiang L; Zhu P
J Clin Immunol; 2013 Jan; 33(1):151-61. PubMed ID: 22926407
[TBL] [Abstract][Full Text] [Related]
20. Tumor necrosis factor inhibitors prevent structural damage in hips in ankylosing spondylitis-time to reconsider treatment guidelines? A case series and review of literature.
Rocha FAC; Pinto ACMD; Lopes JR; Deodhar A
Clin Rheumatol; 2021 May; 40(5):1881-1887. PubMed ID: 33230684
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
